Monoclonal Antibodies as Long-Acting Products: What Are We Learning from Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?

Abstract

Broadly neutralizing antibodies directed against human immunodeficiency virus (HIV) offer promise as long-acting agents for prevention and treatment of HIV. Progress and challenges are discussed. Lessons may be learned from the development of monoclonal antibodies to treat and prevent COVID-19.